<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04551170</url>
  </required_header>
  <id_info>
    <org_study_id>IND 133103 R01</org_study_id>
    <nct_id>NCT04551170</nct_id>
  </id_info>
  <brief_title>Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old</brief_title>
  <official_title>Phase 2 Study of Theophylline Treatment for Pseudohypoparathyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized&#xD;
      by early-onset obesity, short stature and resistance to multiple hormones. This phase 2&#xD;
      clinical trial and open-label extension study will test the efficacy of theophylline, a&#xD;
      phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline&#xD;
      will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance&#xD;
      in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pseudohypoparathyroidism (PHP) is a rare, genetic disorder caused by impaired stimulatory G&#xD;
      protein (Gsα) signaling through downregulation of the gene, GNAS. The resultant hormone&#xD;
      abnormalities can be treated with hormone replacement therapy, but other aspects of the&#xD;
      disorder such as early-onset obesity and short stature are without effective treatment&#xD;
      options. Gsα signaling is essential for the normal hormonal function of the pituitary,&#xD;
      thyroid, gonads, renal proximal tubules and hypothalamus. While many of the resulting hormone&#xD;
      deficiencies can be treated with hormone replacement therapy (HRT), HRT is not an effective&#xD;
      therapy for the severe early-onset obesity and short stature which are major features of the&#xD;
      PHP phenotype. Therefore, the goal of this clinical trial is to test the efficacy of upstream&#xD;
      therapy aimed at correcting the function of Gsα-dependent receptors in children with PHP.&#xD;
      Gsα-coupled receptor signaling cascade begins with an increase in cyclic adenosine&#xD;
      monophosphate (cAMP) which is rapidly degraded by the enzyme phosphodiesterase (PDE). PDE&#xD;
      inhibitors act by prolonging cAMP signaling by decreasing the rate of degradation. Given that&#xD;
      patients with PHP have reduced, but not completely absent, cAMP production, the investigators&#xD;
      seek to test the hypothesis that the PDE inhibitor theophylline will reduce body mass index&#xD;
      (BMI), slow the rate of epiphyseal closure, and decrease hormone resistance in children with&#xD;
      PHP through improved Gsα-coupled receptor signaling. The investigators will conduct a 52-week&#xD;
      randomized, placebo-controlled clinical trial of theophylline in children with PHP.&#xD;
      Theophylline is a non-selective PDE inhibitor that is generically available and has a long&#xD;
      history of use in pediatric patients, making it an ideal drug for repurposing in youth with&#xD;
      PHP. Furthermore, the pharmacokinetics of theophylline are well understood, and serum drug&#xD;
      levels are easily measured. Our primary outcome is change in BMI. Secondary outcome measures&#xD;
      include change in epiphyseal closure and HRT medication doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body mass index</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>BMI expressed as percent of the 95th percentile</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in levothyroxine dose</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>levothyroxine dose (mcg/kg/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calcitriol dose</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>calcitriol dose (mcg/kg/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in epiphyseal closure</measure>
    <time_frame>baseline and 52 weeks</time_frame>
    <description>Bone age minus chronologic age</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Pseudohypoparathyroidism</condition>
  <condition>Albright Hereditary Osteodystrophy</condition>
  <condition>Pseudohypoparathyroidism Type 1a</condition>
  <arm_group>
    <arm_group_label>Theophylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Theophylline capsules by mouth once daily or Theophylline elixir by mouth q6h (dose determined by serum drug levels)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule by mouth once daily or Placebo elixir by mouth q6h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline</intervention_name>
    <description>oral theophylline</description>
    <arm_group_label>Theophylline</arm_group_label>
    <other_name>Theo-24</other_name>
    <other_name>Elixophyllin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule or elixir</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 2 to 12 years old&#xD;
&#xD;
          -  Clinical diagnosis of PHP (per the EuroPHP network classification guidelines5):&#xD;
             Presence of PTH resistance and/or ectopic ossification OR brachydactyly type E plus 2&#xD;
             minor criteria (TSH resistance, other hormonal resistance, developmental delay,&#xD;
             intrauterine or post-natal growth retardation, obesity/overweight, specific facial&#xD;
             features)&#xD;
&#xD;
          -  Obesity (BMI &gt;95th percentile for age/gender and/or ≥30 kg/m2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of a PDE inhibitor in the past 30 days&#xD;
&#xD;
          2. History of a seizure disorder unrelated to hypocalcemia&#xD;
&#xD;
          3. History of a cardiac arrhythmia (not including bradycardia)&#xD;
&#xD;
          4. Hepatic insufficiency including cirrhosis and acute hepatitis (AST or ALT &gt;3x upper&#xD;
             limit of normal)&#xD;
&#xD;
          5. Congestive heart failure&#xD;
&#xD;
          6. Current cigarette use or alcohol abuse&#xD;
&#xD;
          7. Pregnancy or intention to become pregnant during the next year&#xD;
&#xD;
          8. Untreated hypothyroidism (defined as free thyroxine below the lower limit of normal)&#xD;
&#xD;
          9. Active peptic ulcer disease&#xD;
&#xD;
         10. Current use of medications known to effect theophylline levels (see protection of&#xD;
             human subjects)&#xD;
&#xD;
         11. History of hypersensitivity to theophylline or other medication components&#xD;
&#xD;
         12. History of Major Depressive Disorder in the past 2 years, lifetime history of suicide&#xD;
             attempt, history of any suicidal behavior in the past month, history of other sever&#xD;
             psychiatric disorders (e.g. schizophrenia, bipolar disorder)&#xD;
&#xD;
         13. PHQ-9 score is ≥15 or suicidal ideation of type 4 or 5 (C-SSR) in the past month&#xD;
&#xD;
         14. Untreated hypothyroidism or uncontrolled PTH resistance (PTH &gt;2x upper limit of&#xD;
             normal), or treatment of these disorders by medications other than calcitriol or&#xD;
             levothyroxine (such as Cytomel or Armour thyroid)&#xD;
&#xD;
         15. Unable to comply with study procedures in the opinion of the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ashley Shoemaker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Wright, RN</last_name>
    <phone>6153438116</phone>
    <email>sarah.e.wright@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ashley Shoemaker, MD</last_name>
    <phone>6153438116</phone>
    <email>ashley.h.shoemaker@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Shoemaker, M.D.</last_name>
      <phone>615-343-8116</phone>
      <email>ashley.h.shoemaker@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Ashley Shoemaker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.facebook.com/pseudohypoparathyroidism</url>
    <description>Vanderbilt PHP Research Page</description>
  </link>
  <reference>
    <citation>Shoemaker AH, Jüppner H. Nonclassic features of pseudohypoparathyroidism type 1A. Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):33-38. doi: 10.1097/MED.0000000000000306. Review.</citation>
    <PMID>27875418</PMID>
  </reference>
  <reference>
    <citation>Wang L, Shoemaker AH. Eating behaviors in obese children with pseudohypoparathyroidism type 1a: a cross-sectional study. Int J Pediatr Endocrinol. 2014;2014(1):21. doi: 10.1186/1687-9856-2014-21. Epub 2014 Oct 15.</citation>
    <PMID>25337124</PMID>
  </reference>
  <reference>
    <citation>Mano T, Uchimura K, Hayashi R, Kobahashi T, Fujiwara K, Makino M, Kakizawa H, Nagata M, Nakai A, Wada M, Nagasaka A, Itoh M. Increased urinary phosphate excretion in pseudohypoparathyroidism type II with long-term treatment with phosphodiesterase inhibitor. Horm Metab Res. 1999 Nov;31(11):602-5.</citation>
    <PMID>10598827</PMID>
  </reference>
  <reference>
    <citation>Landreth H, Malow BA, Shoemaker AH. Increased Prevalence of Sleep Apnea in Children with Pseudohypoparathyroidism Type 1a. Horm Res Paediatr. 2015;84(1):1-5. doi: 10.1159/000381452. Epub 2015 Apr 23.</citation>
    <PMID>25925491</PMID>
  </reference>
  <reference>
    <citation>Perez KM, Lee EB, Kahanda S, Duis J, Reyes M, Jüppner H, Shoemaker AH. Cognitive and behavioral phenotype of children with pseudohypoparathyroidism type 1A. Am J Med Genet A. 2018 Feb;176(2):283-289. doi: 10.1002/ajmg.a.38534. Epub 2017 Nov 28.</citation>
    <PMID>29193623</PMID>
  </reference>
  <reference>
    <citation>Curley KL, Kahanda S, Perez KM, Malow BA, Shoemaker AH. Obstructive Sleep Apnea and Otolaryngologic Manifestations in Children with Pseudohypoparathyroidism. Horm Res Paediatr. 2018;89(3):178-183. doi: 10.1159/000486715. Epub 2018 Feb 16.</citation>
    <PMID>29455209</PMID>
  </reference>
  <reference>
    <citation>Hanna P, Grybek V, Perez de Nanclares G, Tran LC, de Sanctis L, Elli F, Errea J, Francou B, Kamenicky P, Linglart L, Pereda A, Rothenbuhler A, Tessaris D, Thiele S, Usardi A, Shoemaker AH, Kottler ML, Jüppner H, Mantovani G, Linglart A. Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. J Bone Miner Res. 2018 Aug;33(8):1480-1488. doi: 10.1002/jbmr.3450. Epub 2018 Jun 7.</citation>
    <PMID>29693731</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Ashley Shoemaker</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Pseudohypoparathyroidism</keyword>
  <keyword>PHP</keyword>
  <keyword>AHO</keyword>
  <keyword>Albright Hereditary Osteodystrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudohypoparathyroidism</mesh_term>
    <mesh_term>Pseudopseudohypoparathyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

